Pindolol availability in hypertensive patients with normal and impaired renal function

Area of Science:

• Pharmacology
• Nephrology
• Clinical Pharmacy

Background:

• Hypertension management requires understanding drug pharmacokinetics.
• Renal function significantly impacts drug metabolism and excretion.
• Pindolol is a beta-blocker used for hypertension.

Purpose of the Study:

• To investigate the pharmacokinetics of pindolol in hypertensive patients with normal and impaired renal function.
• To determine how chronic renal failure affects pindolol absorption and elimination.
• To identify specific pharmacokinetic parameters altered by reduced kidney function.

Main Methods:

• A pharmacokinetic study involving 18 hypertensive patients (9 normal, 9 impaired renal function).
• Administration of both intravenous and oral pindolol doses.
• Analysis using a linear two-compartment model and the Loo-Riegelman method.
• Correlation of absorption rates with creatinine clearance.

Main Results:

• Chronic renal failure patients showed decreased total body clearance and renal clearance of pindolol.
• Transfer rate constants and distribution volumes remained unchanged in renal failure.
• Pindolol absorption kinetics were non-first order, with a decreased fraction of dose absorbed and increased initial absorption rate in renal failure.
• Initial absorption rate inversely correlated with creatinine clearance.

Conclusions:

• Chronic renal failure significantly modifies pindolol absorption kinetics.
• Reduced renal clearance contributes to decreased total body clearance of pindolol in renal failure.
• These pharmacokinetic alterations in renal impairment necessitate careful consideration for pindolol dosing in hypertensive patients with kidney disease.